More than 400 Chinese products will be temporarily exempted from tariffs that President Donald Trump's administration imposed last year.China Economyread more
Apple will get a taste of whether upgraded features on the new iPhone 11 are enough to lure shoppers to retail stores around the world as the new smartphones officially hit...Technologyread more
The complaint made by an unnamed intelligence official about the president centers on Ukraine, the Washington post reported.Politicsread more
As tensions might drag over the next decade, investors have to learn to operate under prolonged uncertainty, said Warburg Pincus' Charles Kaye.World Economyread more
U.S. Vice President Mike Pence on Thursday struck an unyielding tone on America's position in its trade war with China.Delivering Alpharead more
Billionaire investor Howard Marks, the co-chairman of Oaktree Capital, predicts there won't be a recession in the U.S. for another two years.US Economyread more
Network officials also said voters should expect more of a Koch focus on grassroots activism throughout the 2020 election cycle.Politicsread more
One person was killed and five others wounded on Thursday in a shooting on the streets of Washington, D.C., not far from the White House, police said.U.S. Newsread more
Stores are extending hours and cities are spending on light shows as China tries to encourage consumers to spend more money at night.China Economyread more
New research suggests fewer girls pursue careers in STEM — science, technology, engineering and math — because they're better than boys at reading.Closing The Gapread more
Stocks in Asia Pacific edged up on Friday as investors digested a series of developments overnight on the U.S.-China trade front that dampened hopes of a deal being reached...Asia Marketsread more
Sometimes Jim Cramer tells a caller that he needs to do homework before he can make a decision on a stock. And he's not kidding.
Following is Cramer's research or homework on stocks recently called to his attention by investors who watch the TV show.
On March 17th, Michael in Illinois asked about Inovio, then on Thursday's Lightning Round, Chris in New York asked about the same name.
"I don't know enough about this stock to opine," said Cramer at the time. "I need to do some homework."
Fortunately Cramer is a quick study. In a day's time, he's learned that Inovio is a small biotech company that has run from about $0.50/share a year ago to well over $3/share today.
Largely the gains are pegged to the promise of vaccines made by the company that are used in the treatment of cancers and infectious diseases. "The company's SynCon technology enables vaccines to protect patients from changing strains of pathogens, including influenza and HIV. And the clinical programs include cervical dysplasia, avian influenza, prostate cancer, leukemia, Hep C and HIV. "
Cramer always says "Mad Money" viewers are among the smartest investors that he knows. And this is no exception. He thinks viewers have found a potential buy.
"I believe that the pipeline breadth makes an interesting spec," he said. But, as with every spec play, Cramer also added a word of caution. "If you go into this stock, you must realize it's a bet on a very early stage pipeline and the bet could go wrong."
On March 11th, Rowland in Massachusetts asked about Turquoise Hill, formerly Ivanhoe Mines.
Cramer's research shows that the company is an international exploration and development mining company with significant assets in Mongolia.
Although Cramer can see Turquoise Hill becoming a top copper producer, he wouldn't put money to work here, even with shares down 45% year to date. "There's a dispute with the government of Mongolia over the mines. Who knows how it will play out? Typically I stay away from stocks facing such uncertain catalysts."
Read More Mad Money with Jim Cramer
Foreboding pervades market
New company lands on Cramer's radar
Don't put your money here!
On Mach 18th, Mav in California asked about Alimera, a small biotech that specializes in treatments for the eyes..
"It has one advanced product called ILUVIEN that is in development for DME, a disease of the retina that affects individuals with diabetes and can lead to vision loss and blindness," Cramer said.
Although the treatment shows promise, Cramer feels the stock is a somewhat binary bet on the drug's approval in the US.
Call Cramer: 1-800-743-CNBC
Questions for Cramer? email@example.com
Questions, comments, suggestions for the "Mad Money" website? firstname.lastname@example.org